2022
Migraine—Not Just a Numbers Game
Kopel D, Gottschalk C. Migraine—Not Just a Numbers Game. Neurology 2022, 100: 357-358. PMID: 36396450, DOI: 10.1212/wnl.0000000000201566.Peer-Reviewed Original ResearchConceptsPatient-reported outcome measuresSide effectsAbortive medication useMigraine-related qualityQuality of lifePrimary endpointPreventive therapyMedication useHeadache daysMigraine treatmentPatient populationTreatment optionsPreventive treatmentRecent trialsMigraine pathophysiologyNeurologic disordersDrug trialsOutcome measuresPatient confidenceMost headachesPrescription choicesClinical practicePatientsTherapyMore yearsThe importance of an early onset of migraine preventive disease control: A roundtable discussion
Gottschalk C, Basu A, Blumenfeld A, Torphy B, Marmura M, Pavlovic J, Dumas P, Lalvani N, Buse D. The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports 2022, 5: 25158163221134593. DOI: 10.1177/25158163221134593.Peer-Reviewed Original ResearchEarly onsetDisease controlPreventive therapyMigraine activityAnti-calcitonin gene-related peptide monoclonal antibodyMigraine preventive therapyBurden of migrainePeptide monoclonal antibodyRoundtable of expertsMigraine preventionTreatment initiationPreventive benefitsClinical studiesTreatment expectationsClinical relevancePatientsDrug AdministrationPatient advocatesTherapy goalsHealthcare professionalsMonoclonal antibodiesRoundtable meetingPreventionGrey literatureProfessionals' perceptions
2020
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache The Journal Of Head And Face Pain 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.Peer-Reviewed Original ResearchConceptsEptinezumab 100Days/monthDay 1Chronic migrainePreventive efficacyCalcitonin gene-related peptideMonthly migraine daysPercentage of patientsPrevention of migraineGene-related peptideTreatment effectsMigraine preventive effectMigraine daysInitial dosePreventive effectEptinezumabWeek 1MigrainePatientsPlaceboSustained preventionMonoclonal antibodiesEfficacyMonthsNonsignificant results
2015
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Journal Of Psychoactive Drugs 2015, 47: 372-381. PMID: 26595349, DOI: 10.1080/02791072.2015.1107664.Peer-Reviewed Original ResearchConceptsCluster headacheIndoleamine hallucinogensConventional medicationsChronic cluster headachePain syndromePreventative medicationsAlternative medicationsLysergic acid diethylamideHeadache clinicConventional therapyCluster periodHeadacheMedicationsFinal analysisAcid diethylamideHallucinogensFurther investigationMost responsesSignificant numberAdditional evidenceParticipantsRemissionPatientsSyndromeClinic
2001
Functional Magnetic Resonance Imaging of Cocaine Craving
Wexler BE, Gottschalk CH, Fulbright RK, Prohovnik I, Lacadie CM, Rounsaville BJ, Gore JC. Functional Magnetic Resonance Imaging of Cocaine Craving. American Journal Of Psychiatry 2001, 158: 86-95. PMID: 11136638, DOI: 10.1176/appi.ajp.158.1.86.Peer-Reviewed Original ResearchConceptsFunctional magnetic resonance imagingHealthy subjectsCocaine-dependent subjectsMagnetic resonance imagingResonance imagingCocaine addictsReported onsetBrain activationBrain activityRegional brain activationFrontal lobe activationAnterior cingulate activationNeurobiology of addictionCocaine cravingAnterior cingulatePatientsFrontal lobePhysiologic linkSensory areasComparison of groupsDrug cravingDysphoric statesLess activationGeneral abnormalityCingulate activation